reviewed april 2026|next review october 2026|88 physicians psi has verified|80 published studies
Cortexin
Cortexin is a polypeptide complex extracted from bovine brain cortex, registered as a prescription neuroprotective medication in Russia and CIS countries for stroke recovery, traumatic brain injury, and cognitive decline, containing a mixture of low-molecular-weight peptides rather than a single defined molecule.
Evidence landscape: 80 published studies
80 published items. 7 human studies and 70 animal studies.
- 7 Human
- 70 Animal
- 3 Reviews
Not FDA-approved. Registered as a prescription medication in Russia and CIS (Commonwealth of Independent States) countries. Not approved by any Western regulatory authority.
Available by prescription in Russia and CIS countries. Not available through Western pharmaceutical channels. Available as a research compound in some markets.
Polypeptide mixture extracted from bovine brain cortex, not a single defined molecule. Contains low-molecular-weight peptides (1-10 kDa), amino acids, vitamins, and minerals. Similar concept to cerebrolysin (porcine brain extract) but derived from cortical tissue specifically.
PSI Assessment
Registered as a prescription neuroprotective medication in Russia and several CIS (Commonwealth of Independent States) countries, cortexin is a polypeptide complex extracted from bovine brain cortex, not a single molecule. It has been used clinically in Russian neurology for over two decades for stroke recovery, traumatic brain injury, and cognitive decline. The published clinical data comes predominantly from Russian institutions, with limited independent Western verification. Like cerebrolysin (another brain-derived polypeptide mixture already on this platform), cortexin raises the question of whether complex biological extracts can be adequately characterized for pharmaceutical-grade reproducibility.
Used in Russian neurology for over two decades. A polypeptide mixture, not a single molecule. Limited Western verification of the Russian clinical data.
The mechanism involves neurotrophic support from a complex mixture of low-molecular-weight peptides (1-10 kDa), amino acids, vitamins, and minerals extracted from bovine brain cortex. The proposed neuroprotective effects include antioxidant activity, anti-apoptotic signaling, and modulation of neurotransmitter balance. Administration is intramuscular. Unlike single-molecule drugs, the active components are not fully characterized, raising questions about batch-to-batch reproducibility that apply to all biological extract-based therapeutics.
What the evidence supports
Cortexin has been used clinically in Russian neurology for over two decades for stroke recovery, TBI, and cognitive decline. Russian clinical studies report functional improvements in neurological patients. The polypeptide extract provides broad neurotrophic support. Registration as a prescription medication in Russia and CIS countries provides regulatory validation within those systems.
What is not yet established
Whether cortexin's clinical effects would replicate in Western-standard randomized controlled trials. The active peptide components within the extract are not fully characterized. Batch-to-batch reproducibility of a complex biological extract. Whether cortexin offers advantages over the better-characterized cerebrolysin.
Research Evidence
The findings below reflect clinical use in Russian settings and the key gaps in Western validation.
Evidence by condition
Evidence dimensions across cortexin research areas. Stroke recovery has the most clinical data within Russian institutions. TBI (traumatic brain injury) and cognitive decline have clinical use reports. Pediatric neurology has published case series.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Stroke Recovery | ||||
| TBI Recovery | ||||
| Cognitive Decline | ||||
| Pediatric Neurology |
Russian clinical studies report functional improvements in stroke rehabilitation patients receiving cortexin, including cognitive recovery and EEG (electroencephalogram) normalization. Cortexin has been registered as a prescription medication in Russia for over two decades.
Clinical data is published primarily in Russian-language journals. Study designs do not consistently meet Western randomized controlled trial standards. No independent Western replication exists.
Published pediatric studies in Russia describe benefits in perinatal brain injury and developmental delays. Cortexin is used in Russian pediatric neurology practice.
Pediatric use is established within the Russian clinical system but has not been evaluated in Western regulatory frameworks.
As a polypeptide mixture rather than a single defined molecule, the specific active components within cortexin are not fully characterized. Batch-to-batch reproducibility is an inherent challenge for biological extract-based therapeutics.
This limitation applies equally to cerebrolysin and other brain-derived peptide mixtures. It is a fundamental challenge for the entire class, not specific to cortexin.
7 Human|70 Animal|3 Reviews
View all 80 indexed studiesHow Cortexin Works
Cortexin is a polypeptide complex, which means it contains a mixture of small proteins rather than a single defined molecule. It is extracted from bovine (cattle) brain cortex tissue and contains peptide fragments with molecular weights under 10 kDa (kilodaltons, a measure of protein size), along with amino acids, vitamins, and minerals.
A cocktail of small brain proteins extracted from animal brain tissue. May support brain repair by providing the molecular signals that healthy brain tissue uses for maintenance, repair, and recovery after injury.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Polypeptide fractions (MW less than 10 kDa), amino acids, vitamins, and minerals extracted from cerebral cortex. Exhibits antioxidant activity, GABA/glutamate modulation, neurotrophic factor enhancement, and anti-apoptotic signaling in animal and laboratory models. The multi-component nature means that the specific active peptide sequences are not identified and mechanistic attribution to individual components is not possible.
What is Cortexin being studied for?
Researchers are studying Cortexin across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Cortexin overall. This means a compound can have human studies for one condition but only animal data for another.
Stroke Recovery
·Human TrialsRussian clinical data supports use in post-stroke rehabilitation. Published studies report cognitive recovery and EEG normalization in stroke patients receiving cortexin.
Limitations: No Western-standard randomized controlled trials. Clinical data published primarily in Russian-language journals. No independent Western replication.
TBI Recovery
·Animal StudiesUsed clinically in traumatic brain injury recovery in Russia and CIS countries. Published reports describe neurological improvements.
Limitations: Limited controlled data by Western standards. Clinical use reports rather than randomized trials.
Cognitive Decline
·Animal StudiesStudied in age-related cognitive decline within Russian clinical practice. Published data reports improvements in cognitive scores.
Limitations: No Western-standard dementia or cognitive decline trials. Study designs do not consistently meet Western regulatory standards.
Pediatric Neurology
·Animal StudiesUsed in Russian pediatric neurology for perinatal brain injury and developmental delays. Published case series report benefits.
Limitations: No Western pediatric trials. Case series rather than controlled studies. Not evaluated by Western pediatric regulatory frameworks.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not approved by any Western regulatory authority (EMA, MHRA, TGA). Registered as a prescription neuroprotective medication in Russia and CIS countries.
Availability: Available by prescription in Russia and CIS countries. Not available through Western pharmaceutical supply chains. Available as a research compound from some international suppliers.
Class context: Intramuscular injection. Well-tolerated in Russian clinical use over two decades. Rare mild side effects reported. As a biological extract, batch consistency is an inherent consideration. The multi-component nature means individual component safety profiles cannot be isolated.
Cortexin has an established safety record across over two decades of clinical use in Russia. Administration is by intramuscular injection. Reported side effects are rare and mild. As a biological extract from bovine brain tissue, the safety assessment is based on clinical experience rather than the single-molecule pharmacokinetic profiling used in Western drug development.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Cortexin discussion.
Comparison and Related Research
Cortexin is most often compared with other brain-derived peptide mixtures and neuroprotective compounds. The comparisons below outline how each differs.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.Clinical study evaluating cortexin as a neuroprotective agent in patients with ischemic stroke. Treatment was associated with improved neurological recovery outcomes, supporting the use of this brain-derived polypeptide preparation in acute cerebrovascular injury.Skoromets AA et al., 2008 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
- 2.Clinical investigation of cortexin treatment in children with specific language impairment and associated behavioral disorders. The study documented improvements in cognitive and behavioral measures, contributing to the evidence base for cortexin in pediatric neurological applications.Chutko LS et al., 2021 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
- 3.Review of clinical evidence for neuropeptide-based treatments in cerebrovascular disease, with cortexin as a primary focus. Summarized data from multiple clinical studies showing neuroprotective benefits in patients with stroke and chronic cerebrovascular insufficiency.Shavlovskaya OA, 2016 in Zh Nevrol Psikhiatr Im S S Korsakova. View on PubMed
- 4.Experimental study demonstrating that cortexin reduced neuronal swelling and cell destruction in a hemorrhagic stroke model. The neuroprotective mechanism appeared to involve modulation of nitric oxide pathways, providing insight into how this polypeptide preparation preserves brain tissue under ischemic stress.Reutov VP et al., 2009 in Dokl Biol Sci. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.